| 1 | A | B | C | D | E | F |
| --- | --- | --- | --- | --- | --- | --- |
| 2 | Cancer immunotherapy - FDA-approved antibodies |  |  |  |  |  |
| 3 | Antibody | Brand name | Type | Target | Approval date | Approved treatment(s) |
| 4 | Alemtuzumab | Campath | humanized | CD52 | 2001 | B-cell chronic lymphocytic leukemia (CLL) |
| 5 | Atezolizumab | Tecentriq | humanized | PD-L1 | 2016 | bladder cancer |
| 6 | Avelumab | Bavencio | human | PD-L1 | 2017 | metastatic Merkel cell carcinoma |
| 7 | Ipilimumab | Yervoy | human | CTLA4 | 2011 | metastatic melanoma |
| 8 | Ofatumumab | Arzerra | human | CD20 | 2009 | refractory CLL |
| 9 | Nivolumab | Opdivo | human | PD-1 | 2014 | unresectable or metastatic melanoma, squamous non-small cell lung cancer, Renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, classical hodgkin lymphoma |
| 10 | Pembrolizumab | Keytruda | humanized | PD-1 | 2014 | unresectable or metastatic melanoma, squamous non-small cell lung cancer (NSCLC), Hodgkin's lymphoma, Merkel-cell carcinoma (MCC), primary mediastinal B-cell lymphoma (PMBCL), stomach cancer, cervical cancer |
| 11 | Rituximab | Rituxan, Mabthera | chimeric | CD20 | 1997 | non-Hodgkin lymphoma |
| 12 | Durvalumab | Imfinzi | human | PD-L1 | 2017 | bladder cancer non-small cell lung cancer |

Question: What is Ofatumumab used for?
Answer: The Ofatumumab is a human antibody that binds to CD20.